Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
29 mai 2024 08h00 HE
|
Optimi Health Corp.
Optimi Health preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber Scheme.
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
14 mai 2024 08h00 HE
|
Optimi Health Corp.
Optimi Health Receives Certificate of Analysis For GMP MDMA 40mg and 60mg MDMA Capsules.
Optimi Health Provides Corporate Update
10 mai 2024 08h50 HE
|
Optimi Health Corp.
Optimi Health provides corporate update.
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research
09 mai 2024 08h00 HE
|
Optimi Health Corp.
Export Permit granted: Optimi's Shipment of MDMA active pharmaceutical ingredient (API) to Israel marks the Company’s first international export
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
23 avr. 2024 08h18 HE
|
Optimi Health Corp.
Optimi Health announces innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre.
Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute
09 avr. 2024 09h13 HE
|
Optimi Health Corp.
Optimi signs international natural psilocybin supply agreement with New Zealand-Based Mātai Medical Research Institute, on behalf of the Tū Wairua Project.
Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract
02 avr. 2024 07h30 HE
|
Optimi Health Corp.
Optimi receives Certificate Of Analysis for GMP Natural Psilocybin Extract. Company has also completed the in-house encapsulation of 5mg & 10mg psilocybin.
Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference
28 mars 2024 07h30 HE
|
Optimi Health Corp.
Optimi Health secures Presenting Sponsorship at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston, MA.
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University
26 mars 2024 07h30 HE
|
Optimi Health Corp.
Supply agreement marks Optimi’s first international shipment of research-grade active pharmaceutical ingredient (API) MDMA to Israel
Optimi Announces Closing of First Tranche of Non-Brokered Private Placement
28 févr. 2024 07h30 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and...